← Leaderboards
Michael E Pichichero
Rochester General Hospital (Ny)
$8,990,191
Attributed
$9,192,460
Total exposure
5
Grants
5
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $1.4M · FY2007–25$2M$1.5M$1M$500K$0
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$9,192,460 · 5
By mechanism
R01$6,182,995 · 2
U01$1,616,462 · 1
U19$1,218,104 · 1
R03$174,899 · 1
Top collaborators
- Ravinder Kaur1 shared
Most similar at Rochester General Hospital (Ny)
Same institution · by research overlap
- Ravinder Kaur$812,141
- Dabin Ren$173,713
Others in their field
Top investigators on “Child”
- Barbara Driver · Westat, Inc.$244,454,458
- Sharon A Nachman · Johns Hopkins University$212,395,175
- Margaret Juliana McElrath · Fred Hutchinson Cancer Center$195,214,889
- George R Seage · Abt Associates, Inc.$189,009,744
- Carol Nesel · Westat$188,148,170
- Elizabeth A Thom · George Washington University$170,579,744
Research focus
ChildImmune ResponseVaccinesImmuneProteinsImmunityOtitis MediaAcuteLeadFutureMorbidity - Disease RateAntibodiesSerumPathogenesisMiddle EarStreptococcus PneumoniaeTympanostomyChildhoodOtitisInfectionCohortNontypable Haemophilus InfluenzaResponseSampling
Grant awards (22)
A Phase II Study Evaluating the Safety and Efficacy of Whole-Cell Pneumococcal Vaccine (wSp) in Reducing Nasopharyngeal Colonization by Streptococcus pneumoniae in Young Children$794,229
U01 · FY2025 · AI · contact PI
Haemophilus influenzae lipoprotein fusion vaccine and lipoprotein vaccine platform development$404,539
R01 · FY2025 · AI · contact PI
Clinical Core: IDEAL shapes vaccine response, susceptibility to respiratory infectious disease and asthma$191,754
U19 · FY2025 · AI · contact PI
A Phase II Study Evaluating the Safety and Efficacy of Whole-Cell Pneumococcal Vaccine (wSp) in Reducing Nasopharyngeal Colonization by Streptococcus pneumoniae in Young Children$822,233
U01 · FY2024 · AI · contact PI
Clinical Core: IDEAL shapes vaccine response, susceptibility to respiratory infectious disease and asthma$356,182
U19 · FY2024 · AI · contact PI
Clinical Core: IDEAL shapes vaccine response, susceptibility to respiratory infectious disease and asthma$304,714
U19 · FY2023 · AI · contact PI
Clinical Core: IDEAL shapes vaccine response, susceptibility to respiratory infectious disease and asthma$365,454
U19 · FY2022 · AI · contact PI
Immune biomarker discovery in children susceptible to recurrent otitis media$85,182
R03 · FY2022 · AI · contact PI
Immune biomarker discovery in children susceptible to recurrent otitis media$89,717
R03 · FY2021 · AI · contact PI
Immune Responses in Otitis Prone Children$585,306
R01 · FY2016 · DC · contact PI
Immune Responses in Otitis Prone Children$642,800
R01 · FY2015 · DC · contact PI
Immune Responses in Otitis Prone Children$557,036
R01 · FY2014 · DC · contact PI
Immune Responses in Otitis Prone Children$61,440
R01 · FY2014 · DC · contact PI
Immune Responses in Otitis Prone Children$529,185
R01 · FY2013 · DC · contact PI
Immune Responses in Otitis Prone Children$587,036
R01 · FY2012 · DC · contact PI
NTHi Immunity in Young Children$469,017
R01 · FY2011 · DC · contact PI
NTHi Immunity in Young Children$491,882
R01 · FY2010 · DC · contact PI
NTHi Immunity in Young Children$508,772
R01 · FY2009 · DC · contact PI
NTHi Immunity in Young Children$309,776
R01 · FY2009 · DC · contact PI
NTHi Immunity in Young Children$68,800
R01 · FY2009 · DC · contact PI
NTHi Immunity in Young Children$468,167
R01 · FY2008 · DC · contact PI
NTHi Immunity in Young Children$499,239
R01 · FY2007 · DC · contact PI